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Background/aim: Premature birth is a major problem that results in an increased risk of mortality and morbidity. The management of
such infants consists of supraphysiological oxygen therapy, which affects brain development due, in part, to the deterioration caused by
reactive oxygen species (ROS). We showed previously that exogenously administered uridine provides neuroprotection in a neonatal rat
model of hyperoxic brain injury. Hence, the aim of the present study was to investigate the effects of uridine on ROS in the same setting.
Materials and methods: Hyperoxic brain injury was induced by subjecting a total of 53 six-day-old rat pups to 80% oxygen (the
hyperoxia group) for a period of 48 h. The pups in the normoxia group continued breathing room air (21% oxygen). Normoxia +
saline or hyperoxia + saline or hyperoxia + uridine 100 mg/kg or hyperoxia + uridine 300 mg/kg or hyperoxia + uridine 500 mg/kg was
injected intraperitoneally (i. p.) 15 min prior to the hyperoxia procedure. The pups were decapitated and the brains were homogenized
to analyze superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), myeloperoxidase (MPO), and malondialdehyde (MDA)
enzymes as well as DJ-1 (protein deglycase DJ-1) — an oxidative stress-sensitive protein.
Results: Hyperoxia-induced may cause overproduction of oxygen radicals and the oxidant/antioxidant balance may be disturbed in the
brain. Brain MPO and MDA levels were significantly increased in saline-receiving pups exposed to hyperoxia. Brain SOD and GSHPx levels were significantly decreased in saline-receiving pups exposed to hyperoxia. Our results showed that uridine administration
prevented the hyperoxia-induced decrease in SOD and GSH-Px while counteracting the hyperoxia-induced increase in MPO and MDA
in a dose-dependent manner. Uridine also increased the DJ-1 levels in brains of rat pups subjected to hyperoxia.
Conclusion: These data suggest that uridine exhibits antioxidative properties which may mediate the protective effects of uridine in a
neonatal rat model of hyperoxic brain injury.
Key words: Uridine, hyperoxia, antioxidative, neonatal rat, DJ-1

1. Introduction
Premature birth is a major problem all over the world
and preterm infants have increased the risk of mortality
and morbidity despite recent advances in neonatal
medicine [1]. Preterm infants are vulnerable to several
complications including respiratory distress syndrome,
bronchopulmonary
dysplasia,
intestinal
injury,
compromised immune system, and cardiovascular
disorders as well as hearing/vision and neurological
problems [2].
Most preterm infants are exposed to supraphysiological
oxygen therapy during perinatal period in the neonatal
intensive care unit (NICU). Supraphysiological oxygen
therapy in the sensitive period of brain development
affects the developmental processes as a result of hyperoxia
[3,4]. Preterm neonates are especially susceptible to

deterioration caused by reactive oxygen species (ROS) due
to the fact that endogenous radical scavenging systems are
not fully mature [3]. Although ROS is a function of signal
molecules at low concentrations [5,6], its overproduction
causes oxidative stress due to the imbalance between
oxidative and antioxidative systems [7]. As a result,
reactive oxygen radicals are formed, which contribute to
oxidative changes in proteins, lipids, and nucleic acids [8],
and negatively impact the survival of neuronal cells during
development [4,9,10]. In the clinical setting, up to 50% of
surviving preterm infants have been reported to exhibit
cognitive deficits or behavioral problems during the later
stages of development [11].
The level and activity of the most-relevant antioxidant
enzymes, such as superoxide dismutase, catalase (CAT),
and glutathione peroxidase (GPX) change dynamically
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during development and mature stage in the last weeks
of gestation, preparing the fetus for lung respiration [12–
14]. They are essential for preserving cells from exposure
to oxidative damage [15]. On the other hand, the brain
levels of oxidative stress markers myeloperoxidase and
malondialdehyde increased significantly after exposure to
hyperoxia in animals and humans [16,17]. MPO is a highly
potent oxidative enzyme that is capable of inducing both
oxidative and nitrosative stress in vivo [18] and MDA is a
lipid peroxidation product that is one of the most frequently
used markers of oxidative stress [19]. Hence, treatments that
raise the levels of antioxidants and lower those of oxidative
stress markers have been associated with neuroprotective
effects [20].
Uridine is the principal circulating pyrimidine
nucleoside in human circulation [21,22], a constituent
of breast milk [23], and a precursor of brain membrane
phospholipids via the Kennedy pathway [24]. We showed
previously that exogenously administered uridine provides
neuroprotection in neonatal rat models of hypoxic-ischemic
encephalopathy (HIE) [25–27] and hyperoxic brain injury
[28]. The neuroprotection by uridine has been shown to be
mediated by its antiapoptotic [25] and epigenetic effects
(i.e., reducing histone deacetylase activity) [27] in the
neonatal HIE model.
Hence, for the first time, the present study aimed to
investigate the mechanism by which uridine exhibited
neuroprotection in the neonatal rat model of hyperoxic
brain injury [28] with regard to hyperoxia-induced
oxidative stress. For this purpose, the study analyzed the
levels of most relevant oxidative/antioxidative enzymes
and DJ-1 protein (protein deglycase DJ-1, also known as
Parkinson disease protein 7 [PARK7]) [29], an oxidative
stress-sensitive protein which is known to maintain
mitochondrial functions by scavenging reactive oxygen
species (ROS) [29].
2. Materials and methods
2.1. Animals and experimental design
A total of 7 dated pregnant Sprague-Dawley rats were
housed in individual cages at 22 °C with 12h light/dark
cycle with free access to food and water. Dams (mothers of
newborn rats) delivered 6 to 13 pups and the day of birth
was considered postnatal day 1 (P1). A total of 53 pups were
included in the study regardless of gender and their weights
were checked daily. The pups were pooled in wood shavings,
divided randomly, and delivered back to nursing dams.
2.2. Induction of hyperoxic brain injury
The 6-day-old pups were randomly divided into 5 groups as
follows: normoxia + saline (n = 10), hyperoxia + saline (n
= 11), hyperoxia + uridine 100mg/kg (n = 13), hyperoxia +
uridine 300mg/kg (n = 9), and hyperoxia + uridine 500mg/
kg (n = 10).
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From P6 to P8 (48 h), the pups in the normoxia group
were subjected to room air (21% oxygen) while those in
the hyperoxia groups were subjected to 80% continuous
oxygen, as has been described previously [9,17–20,29–31].
The preference for studying P6 pups depended on a precise
calculation obtained at the web site [32], which showed
that brain growth and neurogenesis in developing rat brain
on postconceptional (PC) 27 days correspond to those in
human brain on PC 204 days (29.1 weeks).
Continuous oxygen was maintained in a plexiglas
chamber with 60 × 20 × 20 cm (width × depth × height)
dimensions by a flow-through system. Saline (0.9% NaCl;
0.1 ml/10 g body weight) or uridine (100 mg/kg, 300 mg/
kg, or 500 mg/kg; dissolved in saline) was administered
intraperitoneally (i. p.) once 15 min before the onset of
atmospheric air or oxygen exposure. Doses of uridine
administered in this study were selected from our previous
studies reporting neuroprotective effects in neonatal rat
models of hypoxic-ischemic encephalopathy [25–27] and
hyperoxic brain injury [28]. The oxygen level inside the
chamber was monitored continuously with a MiniOX 3000
oxygen analyzer (Ohio Medical Corporation, Gurnee,
IL, USA) to maintain 80% oxygen saturation. Nursing
dams were switched every 24 h to prevent respiratory
complications. On completion of 48-hour hyperoxic
insult (at P8), the pups were decapitated under deep
anesthesia. Then, the brains were removed and chilled in
liquid nitrogen immediately and analyzed for biochemical
parameters and DJ-1 protein by the Western Blotting [33].
2.3. Biochemical analyses
The brain tissues were homogenized in ice-cold phosphatebuffered saline (PBS, pH 7.4). The homogenates were
utilized to analyze the levels of GSH-Px, SOD, MDA, and
MPO using commercially available ELISA kits (Sunredbio
Technology Co. Ltd., Shanghai, China) according to the kit
procedure.
DJ-1 protein analyses:
Homogenates were boiled in Laemmli buffer [34]
and loaded onto Sodium Dodecyl Sulfate Polyacrylamide
Gel Electrophoresis (SDS-PAGE; Mini Protean II, BioRad, Hercules, CA, USA) at equal protein content
analyzed by the Lowry method [35]. Each sample was run
electrophoretically and protein bands were transferred to
polyvinylidene fluoride (PVDF) membranes (Millipore,
Billerica, MA, USA). The membranes were blocked with
5% nonfat dry milk dissolved in tris buffered saline (TBST)
and incubated overnight with the primary antibody, DJ-1
(1:1000, Cell Signaling Technology, Danvers, MA, USA).
On the following day, the membranes were incubated
with HRP (horse radish peroxidase) bound rabbit anti IgG
secondary antibody (1:5000, Cell Signaling Technology,
Danvers, MA, USA) for 1 h and then visualized by
incubation with enhanced chemiluminescence solution
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(Millipore, Billerica, MA, USA). The protein bands were
scanned by Licor CDigit scanner (LI- COR Biotechnology,
Lincoln, NE, USA), and the density of the bands was
compared using the software of Licor CDigit system.
Following this procedure, the membranes were cleared
with stripping buffer (Thermo Fisher Scientific, Rockford
IL, USA) and then incubated with mouse anti-β-IIItubulin antibody (Millipore, Temecula, CA, USA) used as
a house-keeping protein and the procedure was repeated
with the appropriate secondary antibody.
2.4. Statistical analysis
Statistical analyses were performed using the Sigma Plot
12.0 software. The data were expressed as mean ± standard
error of means (SEM). The Shapiro-Wilk test was used
for determining the normality of the data. When the data
showed a normal distribution and passed the normality
test, the difference between groups was determined by
the parametric One-Way ANOVA followed by the post
hoc Tukey test. On the other hand, when the data failed
the normality test, the difference between the groups
was determined by the nonparametric Kruskal-Wallis H
test followed by the post hoc Dunn’s test with Bonferroni
correction. P < 0.05 was considered statistically significant.
3. Results
3.1. Biochemical analyses
Compared with the normoxia + saline group, the brain
MDA levels of the pups in the hyperoxia + saline group
were significantly increased (P < 0.001) (Figure 1A, Table
1). Uridine treatment at 300 mg/kg and 500 mg/kg in the
pups exposed to hyperoxia reduced brain MDA levels
significantly (P < 0.01 and P < 0.001, respectively), while
uridine at 100 mg/kg did not.
Similarly, the brain MPO levels were increased in
saline-receiving pups exposed to hyperoxia significantly
(P < 0.001) (Figure 1B, Table 1) and compared with the
normoxic group. The enhanced brain MPO levels were
reduced significantly in hyperoxic pups treated with
uridine at 300 mg/kg and 500 mg/kg (P < 0.0 and P <
0.001, respectively) doses, while no change was observed
with 100 mg/kg uridine.
On the contrary, the brain SOD levels of the pups in
the hyperoxia + saline group were significantly decreased
(P < 0.001) (Figure 1C, Table 1) compared to those in the
normoxia + saline group. Treatment with uridine at 300
mg/kg and 500 mg/kg in the pups exposed to hyperoxia
increased brain SOD levels significantly (P < 0.01 and P
< 0.001, respectively), but uridine at 100 mg/kg was not
effective.
In good accord with data derived in SOD analyses, the
levels of GSH-Px in the brains of pups in the hyperoxia
+ saline group were significantly decreased (P < 0.001)
(Figure 1D, Table 1) compared to those in the normoxia

+ saline group, and uridine increased the brain GSH-Px
levels at 300 mg/kg and 500 mg/kg in the pups exposed to
hyperoxia significantly (P < 0.05 and P < 0.01, respectively).
Uridine administered at 100 mg/kg dose was again not
effective.
3.2. Levels of DJ-1 protein
The brain DJ-1 protein levels (expressed as % change in
DJ-1/ β-tubulin ratio) of pups in the hyperoxia + saline
group were significantly (P < 0.001) reduced by about 33%
compared to those in the normoxia + saline group (Figure
2, Table 2). Uridine treatment at 300 mg/kg and 500 mg/kg
in the pups exposed to hyperoxia prevented the decrease
in the brain DJ-1 protein levels significantly (P < 0.01 and
P < 0.001, respectively), but not at 100 mg/kg dose (Figure
2, Table 2).
4. Discussion
These data show that uridine exhibits antioxidative
properties in a neonatal rat model of hyperoxic brain
damage suggesting one mechanism by which uridine
provides neuroprotection in such model [28]. We showed,
for the first time, that a single dose of uridine injected to
P6 pups prevented the hyperoxia-induced decreases in
SOD and GSH-Px levels as well as the hyperoxia-induced
increases in MDA and MPO levels, in a dose-dependent
manner. In addition, uridine treatment also enhanced
the decreased levels of DJ-1, an oxidative stress-sensitive
protein.
Preterm birth is a major health problem for neonates
and their caregivers due to the lack of maturity of organs
and systems, including the brain. Survival rates of preterm
neonates have been increasing with efforts in modern
neonatal intensive care units (NICUs) while the same is
not true for morbidity rates [36,37]. In addition to the
complications observed due to prematurity itself, the fact
that most premature infants receive supraphysiological
oxygen therapy for conditions like cardiac resuscitation
and respiratory distress during their NICU stay [38]
contributes to the morbidities associated especially with
tissues like the intestines [39], lungs [40], retina [41,42],
and the brain [3,10,43].
The fact that extrauterine environment (PaO2 100
mm Hg) is richer in oxygen compared to the intrauterine
environment (PaO2 20–25 mm Hg) renders birth an
oxidative challenge for the newborn. Hence, the fetal to
neonatal transition exposes the newborn to an oxygen-rich
world [3], creating a considerably high risk for oxidative
stress at birth. This risk is additionally exacerbated by the
low efficiency of natural antioxidant systems in preterm
newborns [44,45] and the supraphysiological oxygen
therapy that they receive.
Pathological hallmarks of supraphysiological oxygen
treatment in the brain include enhanced inflammation,
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Figure 1. Brain levels of (A) MDA, (B) MPO, (C) SOD, and (D) GSH-Px in neonatal rats subjected to hyperoxic brain damage.
Hyperoxia+Saline group, *P < 0.05, **P < 0.01 and ***P < 0.001 compared to Normoxia+Saline group. Normoxia+Saline group, #P <
0.05, ##P < 0.01 and ###P < 0.001 compared to Hyperoxia+Saline group.

Table 1. Brain levels of MDA, MPO, SOD, and GSH-Px in neonatal rats subjected to hyperoxic brain damage.
Normoxia
+
Saline

Hyperoxia
+
Saline

Hyperoxia
+
U100

Hyperoxia
+
U300

Hyperoxia
+
U500

MDA (nmol/g protein)

4.35 ± 0.1

5.75 ± 0.2***

5.45 ± 0.2***

4.85 ± 0.1##

4.47 ± 0.1###

MPO (ng/g protein)

3.19 ± 0.1

4.83 ± 0.1***

4.57 ± 0.2***

4.04 ± 0.1**#

3.70 ± 0.1###

SOD (ng/g protein)

7.51 ± 0.2

5.54 ± 0.3***

6.30 ± 0.2

7.09 ± 0.3

7.39 ± 0.3###

GSH-Px (ng/g protein)

17.66 ± 0.6

13.23 ± 0.5***

14.67 ± 0.7*

16.28 ± 0.5#

17.06 ± 0.7##

##

Hyperoxia+Saline group, *P < 0.05, **P < 0.01 and ***P < 0.001 compared to Normoxia+Saline group. Normoxia+Saline
group, #P < 0.05, ##P < 0.01 and ###P < 0.001 compared to Hyperoxia+Saline group.
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Figure 2. Levels of DJ-1 protein in brains of neonatal rats subjected to hyperoxic
damage. Hyperoxia+Saline group, ***P < 0.001 compared to Normoxia+Saline
group. Normoxia+Saline group, ##P < 0.01 and ###P < 0.001 compared to
Hyperoxia+Saline group.
Table 2. Levels of DJ-1 protein in brains of neonatal rats subjected to hyperoxic damage.

% Change in DJ-1/β-tubulin ratio

Normoxia
+
Saline

Hyperoxia
+
Saline

Hyperoxia
+
U100

Hyperoxia
+
U300

Hyperoxia
+
U500

100 ± 2

67.2 ± 2.6***

75.4 ± 4.8***

88.2 ± 5.5##

98.7 ± 3.2###

Hyperoxia+Saline group, ***P < 0.001 compared to Normoxia+Saline group. Normoxia+Saline group, ##P < 0.01 and
0.001 compared to Hyperoxia+Saline group.

oxidative stress, and matrix metalloproteinase activity
accompanied by autophagy, increased apoptotic cell death,
and reduced neuro-glial development in the brain [17–
20,31,46,47]. Hyperoxic insult to the brain is associated
with increased levels of IL-1 b and IL-18 mRNA, oxidized
glutathione (GSSG), MDA [17,47], thiobarbituric
acid reactive substances, and hydrogen peroxide [20].
In addition, hyperoxia changes the balance of the
reactive oxygen species (ROS)-dependent thioredoxin/
peroxiredoxin system and reduces the level of DJ-1, a
hydroperoxide-responsive protein [29].
Various neuroprotective strategies have been
investigated experimentally to reduce hyperoxic brain
damage in preterm neonates including caffeine [20],

P<

###

erythropoietin [17,47,48], dexmedetomidine [31],
topiramate [49], acetylcholinesterase (AChE) inhibitors
[50], and, recently, mesenchymal stem cells [51] and
fingolimod [52].
Uridine is the principal circulating pyrimidine
nucleoside in humans [21,22] and a precursor of membrane
phospholipids [24].
We showed previously that exogenously administered
uridine provides neuroprotection and improves long-term
cognitive deficits [26] by reducing apoptotic cell death [25]
and inhibiting histone deacetylase activity [27] in a rat
model of HIE. In addition, our previous findings showed,
in the hyperoxia model, that uridine administration for
5 consecutive days during continuous hyperoxic insult
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reduced apoptosis in pups’ brains and protected against
long-term cognitive deficits [28]. Although uridine has
been shown to exhibit antiinflammatory effects in models
of pulmonary diseases [53,54] or colitis [55], the effect of
uridine on oxidative stress has not yet been studied.
Hence, the aim of the present study was to investigate
whether uridine prevents oxidative injury as a mechanism
of action in the benefit it provides in neonatal hyperoxic
brain damage. We showed, for the first time, that uridine
exhibits antioxidative properties by preventing the
hyperoxia-induced decreases in SOD and GSH-Px levels
and the increases in MDA and MPO levels, as well as by
enhancing the decreased levels of an oxidative stresssensitive protein, DJ-1. These data provide the first evidence
that the neuroprotective effect of uridine in a neonatal rat
model of hyperoxic brain injury depends, at least in part, on
uridine’s action on oxidative stress parameters.
Our data on SOD, GSH-Px, MDA, and MPO are in good
accord with previous studies reporting that antioxidative
strategies provide neuroprotection in the hyperoxiainduced brain injury in neonatal animals [17–20,31,47].
In addition, we found, in accordance with previous studies
[29], that the levels of DJ-1, an oxidative stress-sensitive
protein, were reduced following supraphysiological oxygen
treatment. DJ-1 functions as a redox-sensitive chaperone

to protect tissues against oxidative stress and cell death
[56–59]. Hence, in cases where DJ-1 levels are decreased,
oxidative stress is triggered, which in turn contributes to
cell death, as shown in a neuronal cell line [60], or in the
immature brain following hyperoxic insult [29]. Therefore,
treatments that raise the expression of DJ-1 protein may
prevent oxidative stress and provide benefit in terms of
neuroprotection. In the present study, we showed that
uridine treatment significantly restored DJ-1 levels in a
dose-dependent manner and this effect may comprise one
mechanism by which uridine prevents brain cell death in
the hyperoxic setting [28].
In conclusion, our data show, for the first time, that
uridine prevents oxidative damage by preventing the
hyperoxia-induced decreases in SOD and GSH-Px levels
and the increases in MDA and MPO levels, as well as by
enhancing the decreased levels of DJ-1 protein. These data
provide a deeper mechanistic insight into the neuroprotective
effect of uridine in neonatal hyperoxic brain injury.
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